Inhibition of CXCR4-mediated signaling has therapeutic efficacy by itself, but can also have a synergistic effect with other anti-cancer drugs, such as bortezomib, melphalan, doxorubicin, and dexamethasone [11]. Here, CXCR4 is linked to cancer.